المؤلفون: James Larkin, Jeffrey S. Weber, F. Stephen Hodi, Paolo A. Ascierto, Roger Olofsson Bagge, Georgina V. Long, Alexander C.J. van Akkooi, Jacob Schachter, Caroline Robert, Lars Ny

المصدر: Melanoma Research. 31:181-185

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Ipilimumab, Dermatology, Pembrolizumab, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Clinical endpoint, Humans, Medicine, Neoplasm Metastasis, Stage (cooking), Melanoma, Randomized Controlled Trials as Topic, business.industry, medicine.disease, Clinical trial, 030104 developmental biology, 030220 oncology & carcinogenesis, Female, Immunotherapy, Nivolumab, business, medicine.drug

الوصف: Nearly 10% of patients with high-risk early-stage melanoma will develop satellite or in-transit metastases (ITM), classified as stage III disease similar to lymph node metastases. The pivotal registration trials of the CTLA-4 antibody ipilimumab, and the PD-1 antibodies nivolumab and pembrolizumab, also included patients with unresectable stage III disease. However, there has been no analysis of patients with ITM, and anecdotal retrospective small series have indicated a potential lesser effect. This study aimed to identify patients with unresectable ITM within the randomized trials, and to determine response, progression-free survival and overall survival. The pivotal phase III randomized intervention trials that included melanoma patients with ITM, with or without nodal metastasis, and were treated with ipilimumab, nivolumab or pembrolizumab was identified. The datasets from each trial were then searched to identify the specific details of the investigated patient population for a pooled analysis. The primary endpoint was complete response rate. Seven trials that included stage III patients, and with accessible datasets, were identified. There was a total of 4711 patients, however, no patients with ITM could be identified, as this data was not captured by the case report forms. Evidence from prospective clinical trials on the use of immunotherapy in patients with ITM is lacking. We recommend pooling data from multiple institutions to examine efficacy of available drug therapies in this patient population, but more importantly, prospective clinical trials of locoregional treatments with or without systemic drug therapies are required.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3a480cb93e62763c98a1eb0a61f5b12Test
https://doi.org/10.1097/cmr.0000000000000719Test

المؤلفون: Caroline Robert, Madona Sakkal, C. Velter

المصدر: Melanoma Research. 30:629-630

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Text mining, Metastatic melanoma, business.industry, Internal medicine, MEDLINE, Medicine, Dermatology, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::370a27ff939575f5556bf4533674a37cTest
https://doi.org/10.1097/cmr.0000000000000667Test

المؤلفون: Ambre Marzouki-Zerouali, Caroline Robert, C. Velter

المصدر: Melanoma Research. 30:529-530

مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, Oncology, business.industry, Ask price, Melanoma, medicine, MEDLINE, Dermatology, medicine.disease, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::7eb954b6a6be0fe17835af4b36123cd4Test
https://doi.org/10.1097/cmr.0000000000000610Test

المؤلفون: Lars Bastholt, Ivan Marquez Rodas, Jochen Utikal, Pier Francesco Ferrucci, Harriet Tuson, Luc Thomas, Miranda Payne, Pascal Wolter, Caroline Robert, J McKendrick, Johan Hansson, Paolo A. Ascierto, Amber Kudlac

المصدر: Melanoma Research
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Ascierto, P A, Bastholt, L, Ferrucci, P F, Hansson, J, Márquez Rodas, I, Payne, M, Robert, C, Thomas, L, Utikal, J S, Wolter, P, Kudlac, A, Tuson, H & McKendrick, J 2018, ' The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma : Results from a European expert panel study ', Melanoma Research, vol. 28, no. 4, pp. 333-340 . https://doi.org/10.1097/CMR.0000000000000455Test

مصطلحات موضوعية: Disease specific, Male, Proto-Oncogene Proteins B-raf, advanced melanoma, Cancer Research, medicine.medical_specialty, Skin Neoplasms, BRAF/MEK inhibitors, medicine.medical_treatment, Delphi method, Patient characteristics, Dermatology, Targeted therapy, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Surveys and Questionnaires, medicine, Humans, Intensive care medicine, Melanoma, Advanced melanoma, business.industry, factors, selecting therapy, medicine.disease, ORIGINAL ARTICLES: Clinical research, expert opinion, First line treatment, Europe, Oncology, first-line treatment decision, 030220 oncology & carcinogenesis, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, Female, Treatment decision making, immunotherapy, business, checkpoint inhibitors

الوصف: Supplemental Digital Content is available in the text.
Treatment decisions for advanced melanoma are increasingly complex and guidelines provide limited advice on how to choose between immunotherapy and targeted therapy for first-line treatment. A Delphi study was carried out to understand which patient characteristics and disease-related factors inform clinicians’ choices of first-line treatment for BRAF-mutated melanoma. Twelve European melanoma specialists experienced in using immunotherapies and targeted agents participated in a double-blind two-phase Delphi study. In phase 1, participants completed a questionnaire developed after reviewing patient characteristics and disease-related factors reported in trials, clinical guidelines, and health technology assessments. Phase 2 was an expert panel meeting to explore outstanding issues from phase 1 and seek consensus, defined as 80% agreement. Twenty patient-related and disease-related characteristics were considered. There was consensus that tumor burden (83% of clinicians) and disease tempo (83%) are very or extremely important factors when selecting first-line treatment. Several components were deemed important when assessing tumor burden: brain metastases (82% of clinicians) and location of metastases (89%). There was consensus that disease tempo can be quantified in clinical practice, but not on a formal classification applicable to all patients. Lactate dehydrogenase level is a component of both tumor burden and disease tempo; all clinicians considered lactate dehydrogenase important when choosing first-line treatment. The majority (92%) did not routinely test programmed death ligand-1 status in patients with melanoma. Clinicians agreed that choosing a first-line treatment for advanced melanoma is a complex, multifactorial process and that clinical judgment remains the most important element of decision-making until research can provide clinicians with better scientific parameters and tools for first-line decision-making.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ee4e9e62e780a228a3f3cccf6e9e120Test
https://pubmed.ncbi.nlm.nih.gov/29750751Test

المؤلفون: Samy Ammari, Salima Hibat-Allah, Frédéric Dhermain, Mathieu Texier, Charlée Nardin, Caroline Robert, Christine Mateus, Emilie Lanoy

المصدر: Melanoma research. 28(2)

مصطلحات موضوعية: 0301 basic medicine, Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Skin Neoplasms, medicine.medical_treatment, Population, Ipilimumab, Dermatology, Pembrolizumab, Antibodies, Monoclonal, Humanized, Radiosurgery, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Agents, Immunological, Internal medicine, parasitic diseases, Clinical endpoint, Medicine, Humans, Neoplasm Metastasis, Prospective cohort study, education, Aged, Retrospective Studies, Aged, 80 and over, education.field_of_study, business.industry, Brain Neoplasms, Melanoma, Chemoradiotherapy, Middle Aged, medicine.disease, 030104 developmental biology, Treatment Outcome, 030220 oncology & carcinogenesis, Female, Nivolumab, business, medicine.drug

الوصف: Anti-programmed cell death-1 (anti-PD1) antibodies are currently the first-line treatment for patients with metastatic BRAF wild-type melanoma, alone or combined with the anti-CTLA4 monoclonal antibody, ipilimumab. To date, data on safety and the outcomes of patients treated with the anti-PD1 monoclonal antibodies, pembrolizumab (PB), or nivolumab, combined with stereotactic radiosurgery (SRS), for melanoma brain metastases (MBM) are scarce. We retrospectively reviewed all patients with MBM treated with PB combined with SRS between 2012 and 2015. The primary endpoint was neurotoxicity. The secondary endpoints were local, distant intracranial controls and overall survival (OS). Among 74 patients with MBM treated with SRS, 25 patients with a total of 58 MBM treated with PB combined with SRS within 6 months were included. Radiation necrosis, occurring within a median time of 6.5 months, was observed for four MBM (6.8%) in four patients. No other significant SRS-related adverse event was observed. After a median follow-up of 8.4 months, local control was achieved in 46 (80%) metastases and 17 (68%) patients. Perilesional oedema and intratumour haemorrhage appearing or increasing after SRS were associated with local progression (P

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf47e8d5161bd7b7d968441998e4af3eTest
https://pubmed.ncbi.nlm.nih.gov/29356789Test

المؤلفون: Christina Mateus, M. Thomas, Caroline Robert

المصدر: Melanoma Research. 24:421-423

مصطلحات موضوعية: Proto-Oncogene Proteins B-raf, MAPK/ERK pathway, Cancer Research, Indoles, Skin Neoplasms, Pyridones, MEDLINE, Pyrimidinones, Dermatology, Computational biology, Text mining, Acneiform Eruptions, Antineoplastic Combined Chemotherapy Protocols, Oximes, medicine, Humans, Vemurafenib, Melanoma, Sulfonamides, business.industry, Imidazoles, MAP Kinase Kinase Kinases, Oncology, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::545763a1367f38c29a1fa4790ee74f70Test
https://doi.org/10.1097/cmr.0000000000000114Test

المؤلفون: Françoise Doyon, Philippe Fragu, Caroline Robert, Ibrahima Diallo, Jean Chavaudra, Marie-Gabrielle Dondon, Catherine Paoletti, Marie-Françoise Avril, D. Lefkopoulos, Nadia Haddy, Akhtar Shamsaldin, Martine Labbé, Florent de Vathaire, Abdeddahir Mousannif

المصدر: Melanoma research. 22(1)

مصطلحات موضوعية: Oncology, Male, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Adolescent, medicine.medical_treatment, Population, Dermatology, Hemangioma, Cohort Studies, Risk Factors, Internal medicine, medicine, Humans, Risk factor, education, Child, Radiation Injuries, Melanoma, education.field_of_study, Radiotherapy, business.industry, Case-control study, Infant, medicine.disease, Radiation therapy, Case-Control Studies, Child, Preschool, Cohort, Female, business, Cohort study

الوصف: The aim of this study was to determine therapy-related risk factors for the development of melanoma after hemangioma. A cohort study was conducted among 4620 patients treated before 16 years of age for skin hemangioma in France. A nested case-control study was also conducted on 13 patients who developed a melanoma (cases) matched with five controls in cohort according to sex, age at the hemangioma diagnostic, the calendar year of occurrence of the hemangioma, and follow-up. The radiation dose received at the site of the melanoma and at the same site in controls was estimated, and named 'local dose'. A total of 13 melanomas were registered during an average follow-up of overall 35 years, the risk of developing melanoma after a hemangioma treatment was 2.5-fold higher [95% confidence interval (CI): 1.4-4.1] compared with that of the general population, this ratio being only 0.8 (95% CI: 0.05-3.6) in 896 patients who did not receive radiotherapy, but 3.0 (95% CI: 1.6-5.1) after radiotherapy. When adjusting on sex, age, and year of the treatment and follow-up duration, melanoma risk was 11.9 (95% CI: 1.4-123) times higher in patients treated with ytrium 90 than in the ones who did not received radiotherapy. In the case-control study, the risk of melanoma was not linked to the local radiation dose. Indeed, the increase in melanoma risk was observed even for very low local doses. Compared with the corresponding skin areas in patients who did not receive radiotherapy, the ones having received less than 0.001 Gy had a melanoma risk of 3.9 (95% CI: 0.5-32) and those who received more than 0.01 Gy had a risk of 6.9 (0.5-99). This study suggests that radiation therapy of skin hemangioma increases the risk of further melanoma, but we were not able to evidence a relation with the local dose. Nevertheless, childhood treated for hemangioma should be considered at risk for developing melanoma and suspicious pigmented lesions should be carefully evaluated even far from treated areas.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28018b2ceaee3f877a90677fb630f179Test
https://pubmed.ncbi.nlm.nih.gov/22082956Test